Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

Autor: Vincent Camus, Aurélien Belot, Lucie Oberic, David Sibon, Hervé Ghesquières, Catherine Thieblemont, Christophe Fruchart, Olivier Casasnovas, Jean-Marie Michot, Thierry Jo Molina, André Bosly, Clémentine Joubert, Corinne Haioun, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Olivier Fitoussi, Richard Delarue, Hervé Tilly

Publikováno v: Blood Advances. 6:6169-6179

The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-line rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in patients with diffuse l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7069ad46fc2c733b31e08cbbb2c18dc2
https://doi.org/10.1182/bloodadvances.2022007609

Data from Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

Autor: Fabrice Jardin, Karen Leroy, Hervé Tilly, Gilles Salles, Nicolas Ketterer, Marc André, André Bosly, Frédéric Peyrade, Richard Delarue, Bertrand Coiffier, Bettina Fabiani, Danielle Canioni, Tony Petrella, Josette Brière, Christiane Copie-Bergman, Thierry Lamy, Corinne Haioun, Thierry Fest, Fabienne Desmots, Thierry J. Molina, Martin Figeac, Pauline Peyrouze, Jean-Philippe Jais, Catherine Maingonnat, Philippe Ruminy, Philippe Bertrand, Elodie Bohers, Sylvain Mareschal, Pierre-Julien Viailly, Sydney Dubois

Purpose: Next-generation sequencing (NGS) has detailed the genomic characterization of diffuse large B-cell lymphoma (DLBCL) by identifying recurrent somatic mutations. We set out to design a clinically feasible NGS panel focusing on genes whose muta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1892cd8fb1dd9d95dbbcc3540a90e602
https://doi.org/10.1158/1078-0432.c.6523979.v1

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Autor: Bernardo Garichochea, Judit Demeter, Yuankai Shi, Umberto Vitolo, Enrica Morra, Margarida Marques, Miklos Egyed, Toshiki Uchida, Árpád Illés, Kenichi Ishizawa, Cristina Ligia Cebotaru, Ashis Mukhopadhyay, Masafumi Taniwaki, Sung-Soo Yoon, Cristina-Ligia Truica, Cheol Won Suh, Irina Lysenko, Naokuni Uike, Huaqing Wang, Achiel Van Hoof, Maryna Kyselyova, Osmanov Ea, Andrew Belch, Alexy Kuzmin, Caballero Gabarrón, Steven Van Steenweghen, Sergio Cancelado, Olga Samoilova, Kensei Tobinai, Kiyoshi Ando, Susumu Nakahara, Tatiana Scheider, Massimo Federico, Dmitry Udovitsa, Xiaoyan Ke, Yurii Lorie, Tatsu Shimoyama, Weerasak Nawarawong, Sebastian Grosicki, Gregor Verhoef, Nuriet Khuageva, Suporn Chuncharune, Fritz Offner, Albert Oriol Rocafiguera, Charles Farber, Ernst Späth-Schwalbe, Juliana Pereira, Ting Liu, Lee-Yung Shih, Steven Le Gouill, Miklos Udvardy, Richard Greil, Carmen Cao, Tomohiro Kinoshita, Horia Bumbea, Yasuhito Terui, Eva Gonzalez-Barca, Irina Bulavina, Peter Hu, Francisco Javier Capote, Olga Serduk, Akihiro Tomita, Ilseung Choi, Mahmut Gumus, Udomsak Bunworasate, Adriana Teixeira, Vladimir Merkulov, Yeow Tee Goh, Tadeusz Robak, Huiqiang Huang, Jie Jin, Cristina Ileana Burcoveanu, Halyna Pylypenko, Joaquín Díaz, Herlander Marques, Zoltán Gasztonyi, Vijay Rao Phooshkooru, Gayane Tumyan, Maike De Wit, Ali Khojasteh, Marcelo Capra, Vladimir Lima, Dai Maruyama, Viacheslav Pavlov, Georg Heß, Carmino Antonio De Souza, Zhao Wang, Iryna Kryachok, Amel Mezlini, Galvez Cardenas, Marina Golubeva, Lyudmila Kuzina, Patricia Santi, Remy Gressin, Balkis Meddeb, Xiaonan Hong, David Belada, Bernard De Prijck, Jan Maciej Zaucha, Jiri Mayer, Michinori Ogura, Rumiko Okamoto, Dolores, Irit Avivi, Mario Ojeda-Uribe, Grigoriy B Rekhtman, Jun Zhu, Reyes Arranz, Polina Kaplan, André Bosly, Ann Van De Velde, Kenny Mauricio, Yuri Dunaev, Anatoly Golenkov, Oleg Gladkov, Yoshiharu Maeda, Franco Cavalli, Dina Ben Yehuda, Michele Baccarani, Markus Raderer, Razvan Stoia, Carlos Appiani, Zvenyslava Masliak, Zita Borbenyi, Guiseppe Rossi, Julia Alexeeva, Johannes Drach, Kateryna Vilchevskaya, Georgii Manikhas, Jan Novák, Noppadol Siritanaratkul, Zhixiang Shen, Alexander Suvorov, Michael Crump, Pierre Zachee, Ofer Shpilberg, Sepideh Nemat, Mitsutoshi Kurosawa, Sreejith Nair, Bulent Undar, Govind Babu, Kudrat Abdulkadryrov, Adriana Sheliga

Publikováno v: The Lancet Oncology. 19:1449-1458

Summary Background In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c43dd418b74f44f31f1f62f0d52fde6f
https://doi.org/10.1016/s1470-2045(18)30685-5

Pr Bertrand Coiffier

Autor: André Bosly, Gilles Salles, Christian Gisselbrecht, Hervé Tilly, Philippe Gaulard, Corinne Haioun

Publikováno v: Bulletin du cancer, Vol. 106, no. 1, p. 88-89 (2019)

Le professeur Bertrand Coiffier est décédé à l’âge de 71 ans le 02 janvier dernier. Il avait dédié dès le début de sa carrière hospitalo-universitaire tous ses efforts pour développer, en précurseur, la recherche clinique autour des lym

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d8b3ca6b359a1527797a57c0e595b34
https://hdl.handle.net/2078.1/212575

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Autor: Georg Maschmeyer, Bernd Metzner, Corinne Haioun, Richard Delarue, Thomas Fischer, Ulrich Dührsen, Michal Szymczyk, Jan Walewski, Mathias Hänel, Michael Unterhalt, Catherine Thieblemont, Norma Peter, Kamal Bouabdallah, Christiane Pott, Michael Hallek, Vincent Ribrag, Stephan Stilgenbauer, André Bosly, Catherine Sebban, Josef Birkmann, Christian Schmidt, Marie-Hélène Delfau-Larue, Jürgen Finke, Wolfgang Hiddemann, Nicole Brousse, Elizabeth Macintyre, Gilles Salles, Pierre Feugier, Wolfram Klapper, Roswitha Forstpointner, Eva Hoster, Michael Kneba, Rene-Olivier Casasnovas, Martin Dreyling, Lothar Kanz, Reda Bouabdallah, Olivier Hermine

Publikováno v: Lancet
Lancet, Elsevier, 2016, 388 (10044), pp.565-75
The Lancet
The Lancet, Elsevier, 2016, 388 (10044), pp.565-575. <10.1016/S0140-6736(16)00739-X>

Summary Background Mantle cell lymphoma is characterised by a poor long-term prognosis. The European Mantle Cell Lymphoma Network aimed to investigate whether the introduction of high-dose cytarabine to immunochemotherapy before autologous stem-cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d46b95d1ecb6adc707c9b48a69111a9
https://doi.org/10.1016/s0140-6736(16)00739-x